RCS - Angle PLC - PARSORTIX ENABLES STUDY OF CANCER PROGRESSION

AngleAnnouncement

08/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nRSH0612Qa&default-theme=true

RNS Number : 0612Q  Angle PLC  08 July 2025

 For immediate release  8 July 2025

 

ANGLE plc ("the Company")

 

PARSORTIX SYSTEM enableS the study of CANCER PROGRESSION

 

New publication in Nature Genetics using Parsortix identifies CTC clusters as
promising targets to stop the spread of cancer

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the publication of a
peer-reviewed article in Nature Genetics by Professor Nicola Aceto's team at
ETH Zurich, Switzerland. The study utilised the Parsortix(®) system to
investigate the genetic diversity of CTC clusters.

 

Understanding the genetic diversity of CTC clusters is of clinical importance
because these cells are the precursors of progressive disease and metastasis.
Cancer is a highly dynamic process, and cells are known to diversify over time
due to treatment selection pressure and the accumulation of genetic changes.
This leads to the emergence and expansion of new subclones with distinct
characteristics and varying abilities to survive and proliferate. This
process is crucial because it drives cancer development, progression,
resistance to therapy, and relapse and can help in understanding how to
develop effective cancer treatments.

 

This publication provides evidence of genetic diversity in CTC clusters in
breast cancer patient samples and preclinical mouse models. It includes the
finding that some mutations were exclusive to specific cells within CTC
clusters that could therefore be missed by a tissue biopsy. The research in
mouse models reports a higher prevalence of CTC clusters in high-complexity
tumours, with large CTC clusters associated with higher genetic diversity.

 

The genetic diversity reported in this publication points to CTC clusters as
key contributors to genetic diversity in metastasis. The authors believe that
genetic diversity within CTC clusters enhances their metastatic capability by
increasing therapy resistance opportunities, evasion of immune cell attack, as
well as adaptability and survival at a metastatic site. CTC clusters are
therefore important targets to stop the spread of cancer given these are up to
100 times more metastatic than individual CTCs, with metastatic spread
responsible for more than 90% of cancer related deaths.

 

The authors conclude that CTC clusters carry cells from different tumour
clones, and that the assessment of CTCs and CTC clusters using the Parsortix
system may provide insights into genetic diversity that overcomes the spatial
and temporal limitations associated with traditional tissue biopsy.

 

ANGLE's Chief Scientific Officer, Karen Miller, commented:

"We are pleased to see the Parsortix system being used to progress
understanding of the role of CTC clusters in cancer progression and
specifically the role of genetic diversity in enhancing their metastatic
ability. This work builds on the Aceto lab's pioneering investigation into
understanding CTC clusters and targeted therapy to halt the spread of cancer
by targeting CTC clusters."

 

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQDLFBEDLXBBV